Is the Alcoholic/Non‑Alcoholic Fatty Liver Disease Index (ANI) valid for patients with decompensated cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ANI Score Is Not Validated for Decompensated Cirrhosis

The Alcoholic/Non-Alcoholic Fatty Liver Disease Index (ANI) was developed and validated exclusively in patients with steatohepatitis, not decompensated cirrhosis, and should not be used in this population.

Evidence Base and Limitations

The ANI score was originally derived to distinguish alcoholic liver disease (ALD) from non-alcoholic fatty liver disease (NAFLD) in patients with steatohepatitis 1. The model uses four variables: mean corpuscular volume, AST/ALT ratio, body mass index, and gender. While it demonstrated excellent discrimination in the original validation cohorts (c-statistic 0.767-0.989), these populations consisted of hospitalized, ambulatory, and pre-transplantation patients with steatohepatitis—not specifically patients with decompensated cirrhosis 1.

Why This Matters in Decompensated Cirrhosis

Decompensated cirrhosis represents a fundamentally different clinical entity from the steatohepatitis populations where ANI was validated. Key considerations include:

  • Altered laboratory parameters: Patients with decompensated cirrhosis present with jaundice, ascites, variceal bleeding, hepatorenal syndrome, and hepatic encephalopathy 2. These complications profoundly alter the biochemical markers that ANI relies upon, independent of alcohol etiology.

  • Multi-organ dysfunction: Decompensation involves systemic inflammation, circulatory dysfunction, and organ failures that confound the simple laboratory ratios used in ANI 3.

  • Different prognostic priorities: In decompensated cirrhosis, established scores like MELD, Child-Pugh, and CLIF-C AD are validated for mortality prediction 3, 2. The clinical question shifts from etiology determination to risk stratification and transplant candidacy.

Recent Attempts at Application

A 2026 pilot study attempted to use ANI in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) to identify unrecognized alcohol consumption 4. Critically, the authors themselves acknowledge that "the ANI score is not validated to distinguish MetALD from MASLD" and their findings were in patients without decompensation 4. This underscores that even in compensated disease with different etiologies, ANI's utility remains uncertain.

What to Use Instead

For patients with decompensated cirrhosis:

  • Prognostic assessment: Use MELD score, Child-Pugh score, or CLIF-C AD score for mortality prediction 3, 2
  • Etiology determination: Rely on comprehensive clinical history (including collateral informants for alcohol use), pattern of decompensation (ascites predominates in alcoholic cirrhosis), and histopathology when available 2
  • Biomarkers for prognosis: In decompensated cirrhosis, albumin, INR, bilirubin, and platelet count are validated prognostic markers 5, 6

Clinical Pitfall

Do not apply ANI in decompensated cirrhosis assuming it retains diagnostic accuracy. The score's components (MCV, AST/ALT ratio, BMI) are all significantly altered by the metabolic derangements, nutritional deficiencies, and systemic complications inherent to decompensation, regardless of whether alcohol was the original trigger.

Related Questions

How is the Alcoholic/Non‑Alcoholic Fatty Liver Disease Index (ANI) calculated using AST, ALT, BMI, mean corpuscular volume, and the AST/ALT ratio, and how should the resulting score be interpreted to differentiate alcoholic from non‑alcoholic fatty liver disease?
Is there any scoring system that can differentiate alcoholic cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with decompensated cirrhosis?
In a patient with decompensated cirrhosis, normal electrolytes, normal renal function, mildly elevated transaminases (AST 45 U/L, ALT 40 U/L) and bilirubin 1.4 mg/dL, can lorazepam be safely used for sedation?
What diagnostic workup is indicated for a patient with compensated alcoholic cirrhosis presenting with progressive severe bilateral foot pain that began in the right arm and flank?
Are probiotics beneficial for intestinal issues in a stable elderly patient without severe immunosuppression, central venous catheters, or active malignancy?
What components are included in the evaluate step of the Evaluate‑Identify‑Onscene sequence of Pediatric Advanced Life Support (PALS)?
Is dextrose indicated for burn patients, and what specific criteria should be met before administering it?
What is the significance of a low TSH with normal free T3 and free T4, and how should it be evaluated and managed?
What is the recommended chest compression depth during CPR for a post‑pubertal adolescent (≥15 years old)?
What is the appropriate dosage and frequency of oseltamivir oral suspension for a 3‑year‑old child weighing 15 kg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.